New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
Transcript (slightly modified)
There have been a number of developments in oncology treatment in the last year: which of those do you find the most clinically exciting?
There are several. Obviously, we cannot go in oncology without speaking about immunotherapy, the new biologics. Those drugs are potentially changing the landscape as to how we treat patients with lung cancer, melanoma, and others. So I think this is the most critical component as far as developments. We have had several new drugs approved for multiple myeloma for this year and how to sequence these drugs is a challenge.
Another important point of the clinical track that we discuss for the community of oncology physicians is to make sure that we always support clinical trial enrollment. This is the only way we can move the science forward and get our patients to do better. But, I think immunotherapy is the blockbuster for 2016.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen